Hexapeptide-11

What is Hexapeptide-11?

Hexapeptide-11 is a synthetic hexapeptide with the sequence Phe-Val-Ala-Pro-Phe-Pro (FVAPFP), originally isolated from yeast (Saccharomyces cerevisiae) extracts and now produced synthetically for cosmetic use. It is distinguished from other cosmetic peptides (Argireline, Matrixyl, GHK-Cu, Decapeptide-12) by its proposed mechanism — rather than mimicking a neurotransmitter fragment (Argireline), a collagen propeptide (Matrixyl), or a tyrosinase inhibitor (Decapeptide-12), Hexapeptide-11 is framed as a proteostasis modulator: in cultured fibroblasts it raises expression of proteasome, autophagy, and chaperone genes, increases proteasome activity, and pushes the antioxidant regulator Nrf2 into the cell nucleus. This places it in a small category of cosmetic peptides with a cellular-housekeeping mechanism rather than a structural or enzymatic target. Human data are thin: the only published test of the peptide on its own is a 25-volunteer, 4-week half-face study run by the ingredient supplier, which found a change in one of two skin-elasticity readings. Everything else is cell-culture work. Hexapeptide-11 (CAS 161258-30-6) has a molecular weight of 676.8 Da.

What Hexapeptide-11 Is Investigated For

Hexapeptide-11 is investigated as a topical cosmetic peptide with a distinctive mechanism — it raises proteasome activity, switches on autophagy and chaperone genes, and activates the Nrf2 antioxidant response in cultured human lung and skin fibroblasts. In normal human fibroblasts it protected against hydrogen-peroxide-induced premature senescence, and in a 25-volunteer, 4-week half-face study a toner containing it improved one cutometer elasticity reading (Ue) but not the other (Uf). The mechanistic story is interesting because proteostasis decline is a recognized hallmark of aging, and most cosmetic peptides don't target this layer. The caveats are substantial: the published evidence comes primarily from two industry-linked papers — a 2013 cell study by the ingredient's developer, Arch Personal Care, and a 2015 Redox Biology paper from Ioannis Trougakos's laboratory at the University of Athens with Lonza and Korres co-authors — and independent replication is limited, and human RCT data for topical Hexapeptide-11 on measurable skin outcomes (wrinkle depth, elasticity, pigmentation) is essentially absent. It's best understood as a mechanistically interesting cosmetic ingredient with a thin clinical evidence base rather than a validated anti-aging therapeutic.

History & Discovery

Hexapeptide-11 traces to the long-standing cosmetic interest in yeast (Saccharomyces cerevisiae) extracts, which have been studied for skin since at least 1990, when researchers showed that live yeast cell derivative — an alcohol extract of S. cerevisiae — contains a peptide fraction that stimulates wound healing. The FVAPFP peptide was isolated from yeast ferments by Arch Personal Care Products of South Plainfield, New Jersey (later part of Lonza), then sequenced, made by solid-phase synthesis, and sold as Peptamide 6. Arch's J. Vincent Gruber published the first peer-reviewed study in 2013, reporting that the peptide influenced the onset of senescence in fibroblasts and dermal papilla cells and reversibly lowered ATM and p53. In 2015, Ioannis Trougakos's laboratory in the Department of Cell Biology and Biophysics at the University of Athens — with co-authors from Lonza Personal Care and the Greek cosmetics company Korres — published a mechanistic paper in Redox Biology characterizing FVAPFP as a proteostasis activator in human diploid fibroblasts. That paper remains the dominant primary-literature reference for the ingredient and is the source of essentially every "proteasome activator" and "autophagy activator" marketing claim now attached to Hexapeptide-11. Independent academic replication outside the original group has been sparse, and almost all of the human data are company-run.

How It Works

Hexapeptide-11 is a short peptide originally from yeast that appears to act like a "spring cleaning signal" for skin cells. It activates the cellular machinery that breaks down damaged proteins (proteasome and autophagy) and turns on the antioxidant defense system (Nrf2). In lab studies it helped young fibroblasts resist being pushed into early senescence by hydrogen peroxide, and a supplier study reported it lowered the senescence-related proteins ATM and p53. Whether that translates to visible skin improvement in humans hasn't been rigorously proven, but the mechanism is biologically interesting.

Hexapeptide-11 (FVAPFP) has been characterized primarily through in vitro studies in human diploid fibroblasts — mostly IMR90 embryonic lung fibroblasts, with BJ newborn foreskin fibroblasts used to confirm the gene-expression effects. In the 2015 study, percentages meant percent of a 295 µM stock solution, so the working doses of 2 to 5% were roughly 6 to 15 µM. Exposure to the peptide produces dose- and time-dependent upregulation of: (1) proteasomal subunit expression and peptidase activities, promoting degradation of damaged or oxidized proteins; (2) autophagy-lysosome system genes including BECN1, SQSTM1 (p62), and HDAC6 — although beclin-1 protein did not change and cathepsin B/L activity was unchanged or lower, so a functional increase in autophagy was not shown; (3) mRNA for the heat-shock regulator HSF1 and the chaperones HSP27, HSP70, HSP90, and clusterin (CLU), which refold or escort damaged proteins; and (4) Nrf2 nuclear accumulation with downstream antioxidant response element (ARE) target gene activation. The net cellular effect is suppression of oxidative-stress-induced premature senescence and improved proteostasis capacity. The cellular receptor or primary target protein that mediates these broad transcriptional effects is not fully established — whether Hexapeptide-11 binds a specific surface receptor, translocates into cells, or acts indirectly via surface engagement is not definitively characterized; the 2015 authors wrote that the mode of action remains elusive. They proposed that because the FVAPFP sequence appears in yeast proteins including hsp70, it may act as a pseudo-signal of chaperone activation, or as a low-dose 'hormetic' stressor. Two other findings complicate the anti-aging story: the peptide increased the activity of MMP-2 and MMP-9, enzymes that break down collagen and other matrix proteins, and it slowed fibroblast migration in a scratch assay. In a 25-volunteer, 4-week half-face study, a 2.8% toner improved initial skin elasticity (Ue) but not total deformation (Uf).

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Hexapeptide-11:

• 01Independent replication of the 2015 Trougakos-laboratory proteostasis findings — the mechanistic case rests on two industry-linked primary papers (Gruber 2013; Sklirou 2015), and no other laboratory has repeated the proteasome or Nrf2 experiments.
• 02Whether the MMP-2 and MMP-9 activation seen in cultured fibroblasts happens in skin — these enzymes break down collagen and other matrix proteins, which cuts against a simple anti-aging story, and the finding has not been followed up.
• 03Dose translation — cell studies used about 6 to 15 µM (2015), 0.1 to 1.0% of a supplier solution (2013), and 100 to 400 µg/mL in later keratinocyte and fibroblast work; none link these doses to what a finished product delivers into living skin.
• 04Human RCT data on objective skin outcomes — beyond one 25-person, 4-week supplier-run half-face cutometer test, there is no published double-blind, vehicle-controlled trial of Hexapeptide-11 in isolation measuring wrinkle depth, cutometer-based elasticity, collagen density by ultrasound, or transepidermal water loss in a representative aged-skin population.
• 05Skin penetration and dermal bioavailability — what fraction of applied FVAPFP actually reaches living fibroblasts in intact human skin, and how that fraction depends on formulation (liposomes, penetration enhancers, microneedling), remains essentially unmeasured in the public literature.
• 06Identity of the molecular target — whether Hexapeptide-11 binds a specific receptor, is internalized into cells, acts via a membrane-surface signaling event, or works indirectly through proteolytic fragments has not been resolved, leaving the structure-activity relationship undefined.
• 07Long-term safety of sustained proteasome and autophagy upregulation in epidermal and dermal cells — proteostasis pathways are tumor-suppressive in some contexts and tumor-permissive in others, and chronic pharmacological modulation of these systems in skin has not been studied.
• 08Comparative effect size against established cosmetic actives — head-to-head trials versus retinoids, vitamin C, niacinamide, or peer cosmetic peptides (Argireline, Matrixyl, GHK-Cu) on matched outcomes would let formulators and consumers weigh the ingredient against alternatives with stronger evidence.
• 09Whether the in vitro senescence-suppression finding translates to any measurable change in skin biopsy markers — senescence-associated β-galactosidase staining, p16/p21 expression, SASP cytokines — in humans treated topically.

Forms & Administration

Topical application in serums, creams, and comprehensive anti-aging formulations. Typically included at low concentrations alongside other actives. Skin penetration is a real hurdle: at 676.8 Da, FVAPFP is above the roughly 500 Da size proposed as the practical limit for passive absorption through the stratum corneum, so formulation (liposomal carriers, microneedling-assisted delivery) affects dermal bioavailability. Not for injection. Best used as part of a broader evidence-based skincare regimen rather than a stand-alone anti-aging intervention.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Hexapeptide-11 is a cosmetic ingredient, not a drug, and is not FDA-approved for any indication. Do not inject cosmetic peptide products.

Common Questions

Who Hexapeptide-11 Is NOT For

Drug & Supplement Interactions

Documented drug interactions are not established — systemic absorption from a topical hexapeptide is expected to be low, and no clinical interaction studies have been published. The practical interaction concerns are dermatological rather than pharmacological. Layering Hexapeptide-11 with potent topical actives (prescription retinoids, hydroxy-acid peels at high concentration, benzoyl peroxide, topical corticosteroids) can drive cumulative irritation that obscures both efficacy and tolerability; introduce one active at a time on a several-week cadence. Acidic formulations (low-pH vitamin C serums, AHA/BHA exfoliants) can in theory destabilize peptide bonds via hydrolysis or alter charge state — most stability data for cosmetic peptides recommends separating peptide and low-pH layers by time of day (e.g., vitamin C in the morning, peptides at night) or by minutes within a routine. Oxidants and reactive metal-ion chelators in the same formulation may degrade the peptide during shelf life, which is a formulation-chemistry issue more than a user-level interaction. No clinically meaningful interactions with systemic prescription medications have been reported, consistent with negligible systemic exposure from cosmetic topical use.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions